Qingchun Jin

677 total citations · 1 hit paper
19 papers, 356 citations indexed

About

Qingchun Jin is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Qingchun Jin has authored 19 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Qingchun Jin's work include HER2/EGFR in Cancer Research (8 papers), Breast Cancer Treatment Studies (5 papers) and Cancer Treatment and Pharmacology (4 papers). Qingchun Jin is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Breast Cancer Treatment Studies (5 papers) and Cancer Treatment and Pharmacology (4 papers). Qingchun Jin collaborates with scholars based in United States, Italy and China. Qingchun Jin's co-authors include Nabihah Tayob, Amit G. Singal, Jorge A. Marrero, Neehar D. Parikh, Anand S. Mehta, Austin J. Fobar, Hashem El‐Serag, Sara M. Tolaney, Tari A. King and Paolo Tarantino and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Qingchun Jin

14 papers receiving 353 citations

Hit Papers

Prognostic and Biologic Significance of ERBB2-Low Express... 2022 2026 2023 2024 2022 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer
    2022 147 citations Paolo Tarantino, Qingchun Jin et al. JAMA Oncology profile →

Peers

Qingchun Jin
Ning‐Fu Peng China
Mark Karwal United States
Franz J. Hilke Germany
Gennaro Palmiotti Italy
G. Atalay Belgium
Long-Zi Liu China
Claudia Angela Maria Fulgenzi United Kingdom
Nikoletta Sidiropoulos United States
Laurence Crouzet France
Massimo De Giorgio Italy
Ning‐Fu Peng China
Qingchun Jin
Citations per year, relative to Qingchun Jin Qingchun Jin (= 1×) peers Ning‐Fu Peng

Countries citing papers authored by Qingchun Jin

Since Specialization
Citations

This map shows the geographic impact of Qingchun Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qingchun Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qingchun Jin more than expected).

Fields of papers citing papers by Qingchun Jin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qingchun Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qingchun Jin. The network helps show where Qingchun Jin may publish in the future.

Co-authorship network of co-authors of Qingchun Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Qingchun Jin. A scholar is included among the top collaborators of Qingchun Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qingchun Jin. Qingchun Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
El‐Serag, Hashem B., Camden Lopez, K. Rajender Reddy, et al.. (2025). HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort. Journal of Hepatology. 84(3). 578–586.
2.
Weiss, Anna, Qingchun Jin, Nabihah Tayob, et al.. (2025). Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial. Annals of Surgical Oncology. 33(3). 2275–2283.
3.
Jin, Qingchun, et al.. (2025). Endometrial compaction in patients with chronic endometritis does not predict pregnancy outcomes: a retrospective study. Frontiers in Endocrinology. 16. 1554201–1554201.
4.
Jin, Qingchun, Eileen Wrabel, Adrian Schubert, et al.. (2025). A phase 1b study of Plk1 inhibitor onvansertib in combination with paclitaxel in metastatic triple-negative breast cancer (mTNBC) patients.. Journal of Clinical Oncology. 43(16_suppl). 1100–1100.
5.
Raghavendra, Akshara Singareeka, Qingchun Jin, Melissa Grimm, et al.. (2024). Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆. ESMO Open. 9(11). 103973–103973. 4 indexed citations
6.
Kumthekar, Priya, Qingchun Jin, José Pablo Leone, et al.. (2024). A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer. Clinical Cancer Research. 30(21). 4856–4865. 2 indexed citations
7.
Zañudo, Jorge Gómez Tejeda, Romualdo Barroso‐Sousa, Esha Jain, et al.. (2024). Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nature Communications. 15(1). 2446–2446. 15 indexed citations
8.
El‐Serag, Hashem B., Qingchun Jin, Nabihah Tayob, et al.. (2024). HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 81(2). 465–475. 15 indexed citations
9.
10.
11.
El‐Serag, Hashem B., Nabihah Tayob, Qingchun Jin, et al.. (2023). Mo1129 PHASE 3 BIOMARKER STUDY FOR HCC SURVEILLANCE USING A NOVEL HES V2.0 ALGORITHM. A PROSPECTIVE COLLECTION WITH RETROSPECTIVE BLINDED EVALUATION. Gastroenterology. 164(6). S–767. 1 indexed citations
12.
Weiss, Anna, Qingchun Jin, Adrienne G. Waks, et al.. (2023). Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial. Journal of the American College of Surgeons. 238(3). 303–311. 2 indexed citations
13.
Tarantino, Paolo, Samuel M. Niman, Nolan Priedigkeit, et al.. (2022). HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications. European Journal of Cancer. 174. 277–286. 16 indexed citations
14.
Tarantino, Paolo, Qingchun Jin, Rinath Jeselsohn, et al.. (2022). 1MO Prognostic and biologic significance of HER2-low expression in early breast cancer. Annals of Oncology. 33. S124–S124. 5 indexed citations
15.
Dhindsa, Devinder S., Shivang Desai, Qingchun Jin, et al.. (2022). Circulating progenitor cells and outcomes in patients with coronary artery disease. International Journal of Cardiology. 373. 7–16. 3 indexed citations
16.
Tarantino, Paolo, Qingchun Jin, Nabihah Tayob, et al.. (2022). Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncology. 8(8). 1177–1183. 147 indexed citations breakdown →
17.
Singal, Amit G., Nabihah Tayob, Anand S. Mehta, et al.. (2021). Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology. 20(4). 953–955.e2. 29 indexed citations
18.
Singal, Amit G., Nabihah Tayob, Anand S. Mehta, et al.. (2021). GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. 75(3). 541–549. 115 indexed citations
19.
Chen, Zhe, et al.. (2015). Etanercept Inhibits Pro-inflammatory Cytokines Expression in Titanium Particle-Stimulated Peritoneal Macrophages. Tropical Journal of Pharmaceutical Research. 14(6). 983–983. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ning‐Fu Peng Breakdown of academic impact, for papers by Mark Karwal Breakdown of academic impact, for papers by Franz J. Hilke Breakdown of academic impact, for papers by Gennaro Palmiotti Breakdown of academic impact, for papers by G. Atalay Breakdown of academic impact, for papers by Long-Zi Liu Breakdown of academic impact, for papers by Claudia Angela Maria Fulgenzi Breakdown of academic impact, for papers by Nikoletta Sidiropoulos Breakdown of academic impact, for papers by Laurence Crouzet Breakdown of academic impact, for papers by Massimo De Giorgio
Rankless by CCL
2026